Evaluating buckwheat husk extract for cardiovascular disease risk factors
The Efficacy Evaluation of Buckwheat Husk Extract on Cardiovascular Disease Risk Factors
This study tests if taking buckwheat husk extract daily can help people with certain blood pressure levels lower their risk factors for heart disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 65 Years |
| Sex | All |
| Sponsor | TCI Co., Ltd. Industry-sponsored |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04490720 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the efficacy of buckwheat husk extract in reducing risk factors associated with cardiovascular diseases. It is a double-blind, randomized study where participants will consume either the buckwheat husk extract or a placebo daily for two months. The effectiveness of the intervention will be assessed through clinical evaluations conducted by healthcare professionals. The study focuses on individuals with specific blood pressure ranges to determine the extract's impact on cardiovascular health.
Who should consider this trial
Good fit: Ideal candidates are males and non-pregnant females aged 20 to 65 with specific elevated blood pressure readings.
Not a fit: Patients with a history of major organic diseases or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a natural intervention to help manage cardiovascular disease risk factors.
How similar studies have performed: While the specific use of buckwheat husk extract is novel, similar studies on dietary interventions for cardiovascular health have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 20 to 65-year-old males or non-pregnant females who are willing to sign the subject's consent. 2. The systolic blood pressure is 121-139 mmHg and the diastolic blood pressure is between 81-89 mmHg. 3. Those who are not pregnant and are willing to cooperate with contraception during the trial period. 4. No history of organ transplantation, epilepsy or convulsions, liver or kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history). Exclusion Criteria: 1. Pregnant women. 2. People with a history of organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history). 3. No person has undergone major surgery.
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: Mao-Hsin Lin, Doctor — National Taiwan University Hospital
- Study coordinator: Shyr-Chyr Chen
- Email: scchen@ntu.edu.tw
- Phone: (02) 23123456
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.